Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc (MNPR) is a clinical-stage biopharmaceutical company advancing targeted radiopharmaceuticals for oncology and rare diseases. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and scientific advancements.
Access comprehensive coverage of MNPR's innovative pipeline, including MNPR-101 imaging/therapeutic agents and ALXN-1840 for Wilson disease. Track progress across preclinical studies, partnership announcements, and peer-reviewed research developments.
Our curated news includes updates on uPAR-targeted therapies, clinical trial results, manufacturing partnerships, and strategic collaborations. Content is verified for accuracy and relevance to support informed analysis of MNPR's position in precision oncology.
Bookmark this page for streamlined access to Monopar's latest developments. Check regularly for updates on therapeutic candidates, regulatory filings, and scientific publications driving innovation in radiopharmaceutical cancer treatments.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that Dr. Chandler Robinson, the CEO, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 1:00 to 1:30 pm at the Jefferies Conference Center in NYC.
The company focuses on developing therapeutics aimed at extending life and improving the quality of life for cancer patients. Their pipeline includes camsirubicin (Phase 1b) for advanced soft tissue sarcoma and MNPR-101 for radiopharmaceutical use in advanced cancers. Monopar is committed to enhancing cancer patient care through innovation.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced the completion of a pre-specified interim analysis for its Phase 2b/3 VOICE trial, which aimed to prevent severe oral mucositis in patients with oropharyngeal cancer undergoing chemoradiotherapy. The independent Data Safety Monitoring Board reported that the trial did not meet the pre-defined efficacy threshold of a 15% absolute difference in SOM prevention between Validive and placebo, leading to the discontinuation of the study and Validive's development. Monopar plans to redirect resources towards advancing its Phase 1b camsirubicin trial and MNPR-101 radiopharmaceutical program, stating it has sufficient funds to support activities beyond Q1 2024.
FAQ
What is the current stock price of Monopar Therapeutics (MNPR)?
What is the market cap of Monopar Therapeutics (MNPR)?
